CN109640982A - 奥扎莫德盐酸盐的晶型及其制备方法 - Google Patents
奥扎莫德盐酸盐的晶型及其制备方法 Download PDFInfo
- Publication number
- CN109640982A CN109640982A CN201780051743.3A CN201780051743A CN109640982A CN 109640982 A CN109640982 A CN 109640982A CN 201780051743 A CN201780051743 A CN 201780051743A CN 109640982 A CN109640982 A CN 109640982A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride form
- zhamode
- hydrochloride
- drug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
用于治疗自身免疫疾病，特别是多发性硬化症和溃疡性结肠炎的奥扎莫德盐酸盐的晶型CS3及其制备方法。
Description
PCT国内申请，说明书已公开。
Claims (9)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016108223280 | 2016-09-14 | ||
| CN201610822328 | 2016-09-14 | ||
| PCT/CN2017/101737 WO2018050091A1 (zh) | 2016-09-14 | 2017-09-14 | 奥扎莫德盐酸盐的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109640982A true CN109640982A (zh) | 2019-04-16 |
Family
ID=61619314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780051743.3A Pending CN109640982A (zh) | 2016-09-14 | 2017-09-14 | 奥扎莫德盐酸盐的晶型及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10882830B2 (zh) |
| EP (1) | EP3508481A4 (zh) |
| CN (1) | CN109640982A (zh) |
| WO (1) | WO2018050091A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111223B2 (en) | 2016-06-14 | 2021-09-07 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| US11028060B2 (en) | 2016-08-19 | 2021-06-08 | Receptos Llc | Crystalline forms of ozanimod and processes for preparation thereof |
| EP3508481A4 (en) | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME |
| CN110944982A (zh) * | 2017-08-31 | 2020-03-31 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| US11071471B2 (en) | 2018-02-14 | 2021-07-27 | St. Jude Medical International Holding S.á r.l. | Localized magnetic field transmitter |
| EP4126826A1 (en) * | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102762100A (zh) * | 2009-11-13 | 2012-10-31 | 瑞塞普托斯公司 | 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050411T2 (hu) | 2008-05-14 | 2020-12-28 | Scripps Research Inst | Szfingozin foszfát receptorok új modulátorai |
| FI2291080T5 (fi) | 2008-05-14 | 2023-11-06 | The Scripps Research Institute | Uusia sfingosiinifosfaattireseptorimodulaattoreita |
| EP3062792A1 (en) | 2013-11-01 | 2016-09-07 | Celgene International II Sarl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| CA2981743A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| US11111223B2 (en) | 2016-06-14 | 2021-09-07 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| CN108137516A (zh) | 2016-09-14 | 2018-06-08 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| EP3508481A4 (en) | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME |
| US20200031784A1 (en) * | 2017-04-07 | 2020-01-30 | Solipharma Llc | Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses |
| CN107840830A (zh) | 2017-09-20 | 2018-03-27 | 广东东阳光药业有限公司 | 盐酸奥扎莫德无水晶型i |
-
2017
- 2017-09-14 EP EP17850293.6A patent/EP3508481A4/en not_active Withdrawn
- 2017-09-14 US US16/333,075 patent/US10882830B2/en active Active
- 2017-09-14 WO PCT/CN2017/101737 patent/WO2018050091A1/zh unknown
- 2017-09-14 CN CN201780051743.3A patent/CN109640982A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102762100A (zh) * | 2009-11-13 | 2012-10-31 | 瑞塞普托斯公司 | 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法 |
Non-Patent Citations (2)
| Title |
|---|
| OZANIMOD (RPC1063) IS A POTENT SPHINGOSINE-1-PHOSPHATE RECEPTOR-: "Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune diseasemodifying activity", 《BRITISH JOURNAL OF PHARMACOLOGY》 * |
| 黄世杰: "ozanimod 治疗中重度溃疡性结肠炎的Ⅱ期临床试验显示患者获组织学改善", 《国际药学研究杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3508481A1 (en) | 2019-07-10 |
| WO2018050091A1 (zh) | 2018-03-22 |
| US20190248755A1 (en) | 2019-08-15 |
| US10882830B2 (en) | 2021-01-05 |
| EP3508481A4 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109640982A (zh) | 奥扎莫德盐酸盐的晶型及其制备方法 | |
| CN109563059A (zh) | 奥扎莫德的晶型及其制备方法 | |
| EP3858830B1 (en) | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof | |
| CN109195980B (zh) | 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途 | |
| CN113336768B (zh) | 一种多靶点酪氨酸激酶抑制剂 | |
| WO2019042219A1 (zh) | 奥扎莫德盐酸盐的晶型及其制备方法 | |
| WO2018103726A1 (zh) | 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途 | |
| CN108368115B (zh) | 吡咯并嘧啶化合物的盐 | |
| EP3159349A1 (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
| CN108947974A (zh) | 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途 | |
| WO2018233437A1 (zh) | 巴瑞克替尼的晶型及其制备方法 | |
| WO2023045360A1 (zh) | 大环类化合物的晶型及其制备方法和应用 | |
| WO2019205812A1 (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| WO2019134455A1 (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| CN109476662A (zh) | 一种jak1选择性抑制剂的新晶型及其制备方法和用途 | |
| CN105906616B (zh) | Lde225单磷酸盐的晶型及其制备方法 | |
| CN113260613B (zh) | 一种egfr抑制剂的盐、晶型及其制备方法 | |
| CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| CN105732642B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| TW202104216A (zh) | Plk4抑制劑之結晶型 | |
| WO2017076358A1 (zh) | 咪唑基联苯基化合物盐的新晶型及其制备方法 | |
| CN112154144A (zh) | 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 | |
| CN110036003A (zh) | Ap26113的新晶型及其制备方法 | |
| Zhu et al. | Preparation, characterization, and in vivo evaluation of a polymorphic form of valnemulin hydrogen tartrate | |
| WO2022016420A1 (zh) | 一种喹唑啉酮类化合物的晶型、其制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200902 Address after: California, USA Applicant after: Riseptos Co., Ltd Address before: 215123 Biological Park B4301, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu Applicant before: CRYSTAL PHARMACEUTICAL (SUZHOU) Co.,Ltd. |
|
| CI02 | Correction of invention patent application | ||
| CI02 | Correction of invention patent application |
Correction item: Applicant|Address Correct: Suzhou keruis Pharmaceutical Co., Ltd|215123 Biological nano Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province b4301 False: Riseptos Co., Ltd|California, USA Number: 39-01 Volume: 36 |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201117 Address after: California, USA Applicant after: RECEPTOS, Inc. Address before: 215123 Biological Park B4301, No. 218 Xing Hu Street, Suzhou Industrial Park, Jiangsu Applicant before: CRYSTAL PHARMACEUTICAL (SUZHOU) Co.,Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190416 |